Selected Grants
Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis
ResearchCollaborator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2026ECHO MS
Inst. Training Prgm or CMECollaborator · Awarded by National Multiple Sclerosis Society · 2023 - 2024ECHO MS 2020
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Multiple Sclerosis Society · 2020 - 2022PA Fellowship in Clinical Neuroimmunology
FellowshipPrincipal Investigator · Awarded by Biogen, Inc. · 2017 - 2019An Escalating Multiple Dose Study of ABT-555 in Subjects with Relapsing Forms of Multiple Sclerosis
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2018Susceptibility MRI as a marker for diagnosis and clinical disability in MS
ResearchCo Investigator · Awarded by National Institutes of Health · 2014 - 2017A Phase II, multicenter, randomized, double-blind, parallel gruop, placebo-controlled, adaptive dose-ranging study to eveluate the efficacy and safety of AIN457 (Secuinumab) (IV) inn patients with relapsing mutiple sclerosis.
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2013 - 2016Defining the Functional Role of a Novel MS Susceptibility Gene, IL7R alpha chain
ResearchInvestigator · Awarded by National Institutes of Health · 2009 - 2015Topic Briefs TO#4_Disease Modifying Therapies on Multiple Sclerosis
ResearchInvestigator · Awarded by Patient-Centered Outcomes Research Institute · 2015 - 2015Criterial to Determine Disability Related to Multiple Sclerosis
ResearchInvestigator · Awarded by Agency for Healthcare Research and Quality · 2002 - 2004External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Biogen Idec Inc.
- Bristol-Myers Squibb
- EMD Serono (Merck)
- Genzyme Corporation (Sanofi Aventis)
- Novartis
- vielabio/horizon
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.